
Quiz|Articles|April 17, 2026
OncLive Weekly News Quiz (4/17/2026): Did You See This Week's Updates in CLL, Pancreatic Cancer, and More?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
In the phase 3 BRUIN CLL-322 trial (NCT04965493), which evaluated pirtobrutinib (Jaypirca) in combination with venetoclax (Venclexta) and rituximab (Rituxan) vs venetoclax plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, what was the primary outcome of the study?
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
4
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
5






























































